Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2016, Article ID 1859321, 8 pages
http://dx.doi.org/10.1155/2016/1859321
Research Article

National Trends of Antiparkinsonism Treatment in Taiwan: 2004–2011

1Department of Neurology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan
2Department of Neurology, National Taiwan University Hospital, No. 7, Chunag-Shan South Road, Taipei 100, Taiwan
3Department of Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
4Institute of Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
5Cardiovascular Center, National Taiwan University Hospital, Yun-Lin Branch, Douliou, Yunlin County, Taiwan

Received 7 September 2015; Accepted 21 January 2016

Academic Editor: Jan O. Aasly

Copyright © 2016 Weng-Ming Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. R. Dorsey, R. Constantinescu, J. P. Thompson et al., “Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030,” Neurology, vol. 68, no. 5, pp. 384–386, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. W. M. Liu, R. M. Wu, J. W. Lin, Y. C. Liu, C. H. Chang, and C. H. Lin, “Time trends in the prevalence and incidence of Parkinson's disease in Taiwan: a nationwide, population-based study,” Journal of the Formosan Medical Association, 2015. View at Publisher · View at Google Scholar
  3. M. Di Napoli, “New molecular avenues in Parkinson's disease therapy,” Current Topics in Medicinal Chemistry, vol. 9, no. 10, pp. 913–948, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. R. G. Holloway, I. Shoulson, S. Fahn et al., “Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial,” Archives of Neurology, vol. 61, no. 7, pp. 1044–1053, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. O. Rascol, D. J. Brooks, A. D. Korczyn, P. P. De Deyn, C. E. Clarke, and A. E. Lang, “A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa,” The New England Journal of Medicine, vol. 342, no. 20, pp. 1484–1491, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Katzenschlager, J. Head, A. Schrag, Y. Ben-Shlomo, A. Evans, and A. J. Lees, “Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD,” Neurology, vol. 71, no. 7, pp. 474–480, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. B. S. Connolly and A. E. Lang, “Pharmacological treatment of Parkinson disease: a review,” The Journal of the American Medical Association, vol. 311, no. 16, pp. 1670–1683, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Van Camp, A. Flamez, B. Cosyns, J. Goldstein, C. Perdaens, and D. Schoors, “Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide,” Neurology, vol. 61, no. 6, pp. 859–861, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Pinero, P. Marcos-Alberca, and J. Fortes, “Cabergoline-related severe restrictive mitral regurgitation,” The New England Journal of Medicine, vol. 353, no. 18, pp. 1976–1977, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Zanettini, A. Antonini, G. Gatto, R. Gentile, S. Tesei, and G. Pezzoli, “Valvular heart disease and the use of dopamine agonists for Parkinson's disease,” The New England Journal of Medicine, vol. 356, no. 1, pp. 39–46, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Weintraub, J. Koester, M. N. Potenza et al., “Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients,” Archives of Neurology, vol. 67, no. 5, pp. 589–595, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. T. L. Pitcher, M. R. MacAskill, and T. J. Anderson, “Trends in antiparkinsonian medication use in New Zealand: 1995–2011,” Parkinson's Disease, vol. 2014, Article ID 379431, 9 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. E. A. Osinaga, L. C. A. Inchaurregui, I. E. Ikobaltzeta, N. B. Alonso, and J. G. del Pozo, “A pharmacoepidemiological study of the consumption of antiparkinson drugs in the Basque Autonomous Community (Spain) (1992–2004),” Parkinsonism and Related Disorders, vol. 13, no. 8, pp. 500–504, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Nakaoka, T. Ishizaki, H. Urushihara et al., “Prescribing pattern of anti-Parkinson drugs in Japan: a trend analysis from 2005 to 2010,” PLoS ONE, vol. 9, no. 6, Article ID e99021, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. National Health Insurance Research Database (NHIRD), Introduction to the National Health Insurance Research Database (NHIRD), National Health Insurance Research Database (NHIRD), Taipei, Taiwan, 2010, http://w3.nhri.org.tw/nhird//date_01.html.
  16. E. D. Plowey, S. J. Cherra III, Y.-J. Liu, and C. T. Chu, “Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells,” Journal of Neurochemistry, vol. 105, no. 3, pp. 1048–1056, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. C.-H. Lin, R.-M. Wu, H.-Y. Chang, Y.-T. Chiang, and H.-H. Lin, “Preceding pain symptoms and Parkinson's disease: a nationwide population-based cohort study,” European Journal of Neurology, vol. 20, no. 10, pp. 1398–1404, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. J. de Pedro-Cuesta, I. J. Petersen, L. Stawiarz et al., “High levodopa use in periodically time-clustered, Icelandic birth cohorts. A vestige of parkinsonism etiology?” Acta Neurologica Scandinavica, vol. 91, no. 2, pp. 79–88, 1995. View at Google Scholar · View at Scopus
  19. J. de Pedro-Cuesta, L. Wermuth, V. Abraira, and L. Stawiarz, “Levodopa use in Denmark: high levels in Greenland and the Faroe Islands,” Acta Neurologica Scandinavica, vol. 91, no. 2, pp. 89–97, 1995. View at Google Scholar
  20. Hsueh J. C. T and Y.-T. Wang, “Living arrangement and the well-being of the elderly in Taiwan,” International Journal of Welfare for the Aged, vol. 23, pp. 87–107, 2010. View at Google Scholar
  21. S. Fahn, D. Oakes, I. Shoulson et al., “Levodopa and the progression of Parkinson's disease,” The New England Journal of Medicine, vol. 351, no. 24, pp. 2498–2566, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. PD MED Collaborative Group, “Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial,” The Lancet, vol. 384, no. 9949, pp. 1196–1205, 2014. View at Publisher · View at Google Scholar
  23. J. J. Ferreira, R. Katzenschlager, B. R. Bloem et al., “Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease,” European Journal of Neurology, vol. 20, no. 1, pp. 5–15, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. M. M. Wickremaratchi, Y. Ben-Shlomo, and H. R. Morris, “The effect of onset age on the clinical features of Parkinson's disease,” European Journal of Neurology, vol. 16, no. 4, pp. 450–456, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. Y.-J. Guo, Y.-C. Liao, C.-H. Lin, and M.-H. Chang, “Initial medication in patients of newly diagnosed Parkinson's disease in Taiwan,” PLoS ONE, vol. 9, no. 9, Article ID e107465, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Antonini and W. Poewe, “Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease,” The Lancet Neurology, vol. 6, no. 9, pp. 826–829, 2007. View at Publisher · View at Google Scholar · View at Scopus